HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures

Nature Medicine

Volumn 23, Issue 4, 2017, Pages 517-525

  Davies, Helen ^a   Glodzik, Dominik ^a   Morganella, Sandro ^a   Yates, Lucy R ^a,b   Staaf, Johan ^c   Zou, Xueqing ^a   Ramakrishna, Manasa ^a,d   Martin, Sancha ^a   Boyault, Sandrine ^e   Sieuwerts, Anieta M ^f   Simpson, Peter T ^g   King, Tari A ^h   Raine, Keiran ^a   Eyfjord, Jorunn E ⁱ   Kong, Gu ^j   Borg, Åke ^c   Birney, Ewan ^k   Stunnenberg, Hendrik G ^l   Van De Vijver, Marc J ^m   Børresen Dale, Anne Lise ^n,o   Martens, John W M ^f   Span, Paul N ^p   Lakhani, Sunil R ^g,q   Vincent Salomon, Anne ^r   Sotiriou, Christos ^s   Tutt, Andrew ^t,u   Thompson, Alastair M ^v   Van Laere, Steven ^w,x   Richardson, Andrea L ^y,z   Viari, Alain ^e,aa   Campbell, Peter J ^a   Stratton, Michael R ^a   Nik Zainal, Serena ^a,ab   more..

^a WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c LUND UNIVERSITY   (Sweden)

^d ASTRAZENECA   (United Kingdom)

^e CENTRE LÉON BÉRARD   (France)

^f ERASMUS MC CANCER INSTITUTE   (Netherlands)

^g UNIVERSITY OF QUEENSLAND   (Australia)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁱ UNIVERSITY OF ICELAND   (Iceland)

^j Hanyang University   (South Korea)

^k WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^l RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^m ACADEMIC MEDICAL CENTER   (Netherlands)

ⁿ OSLO UNIVERSITY HOSPITAL   (Norway)

^o UNIVERSITY OF OSLO   (Norway)

^p RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^q ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^r INSTITUT CURIE   (France)

^s JULES BORDET INSTITUTE   (Belgium)

^t KING'S COLLEGE LONDON   (United Kingdom)

^u INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^v UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^w UNIVERSITY OF ANTWERP   (Belgium)

^x HistoGeneX   (Belgium)

^y BRIGHAM AND WOMEN S HOSPITAL   (United States)

^z DANA FARBER CANCER INSTITUTE   (United States)

^aa INRIA   (France)

^ab CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN, HUMAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR;

AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; FEMALE; GENE LOSS; GENE MUTATION; GENETIC PROCEDURES; GERMLINE MUTATION; HRDETECT; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; OVARY CANCER; PANCREAS CANCER; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN DEFICIENCY; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; SOMATIC MUTATION; VALIDATION PROCESS; BIOLOGICAL MODEL; BREAST NEOPLASMS; BREAST TUMOR; DEFICIENCY; DNA MUTATIONAL ANALYSIS; GENETICS; MALE; MUTATION; OVARIAN NEOPLASMS; PANCREATIC NEOPLASMS; STATISTICAL MODEL;

AREA UNDER CURVE; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MODELS, GENETIC; MUTATION; OVARIAN NEOPLASMS; PANCREATIC NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS;

EID: 85015004520     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.4292     Document Type: Article

References (51)

1. Anglian Breast Cancer Study Group. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br. J. Cancer 83, 1301-1308 (2000).
2. John, E.M. et al. Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. J. Am. Med. Assoc. 298, 2869-2876 (2007).
3. Malone, K.E. et al. Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. Cancer Res. 66, 8297-8308 (2006).
4. Couch, F.J., Nathanson, K.L. & Offit, K. Two decades after BRCA: setting paradigms in personalized cancer care and prevention. Science 343, 1466-1470 (2014).
5. King, M.C. "The race" to clone BRCA1. Science 343, 1462-1465 (2014).
6. Lord, C.J. & Ashworth, A. The DNA damage response and cancer therapy. Nature 481, 287-294 (2012).
7. Venkitaraman, A.R. Cancer suppression by the chromosome custodians, BRCA1 and BRCA2. Science 343, 1470-1475 (2014).
8. Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921 (2005).
9. Prakash, R., Zhang, Y., Feng, W. & Jasin, M. Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins. Cold Spring Harb. Perspect. Biol. 7, a016600 (2015).
10. Bryant, H.E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913-917 (2005).
11. Fong, P.C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123-134 (2009).
12. Audeh, M.W. et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376, 245-251 (2010).
13. Tutt, A. et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376, 235-244 (2010).
14. Mateo, J. et al. DNA-repair defects and olaparib in metastatic prostate cancer. N. Engl. J. Med. 373, 1697-1708 (2015).
15. Ledermann, J. et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N. Engl. J. Med. 366, 1382-1392 (2012).
16. Lips, E.H. et al. Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness. Breast Cancer Res. 13, R107 (2011).
17. Ruscito, I. et al. BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients - a study of the Tumour Bank Ovarian Cancer (TOC) and Ovarian Cancer Diagnosis consortium (OVCAD). Eur. J. Cancer 50, 2090-2098 (2014).
18. Jazaeri, A.A. et al. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J. Natl. Cancer Inst. 94, 990-1000 (2002).
19. Larsen, M.J. et al. Classifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by RNA tumor profiling. PLoS One 8, e64268 (2013).
20. Peng, G. et al. Genome-wide transcriptome profiling of homologous recombination DNA repair. Nat. Commun. 5, 3361 (2014).
21. Joosse, S.A. et al. Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH. Breast Cancer Res. Treat. 116, 479-489 (2009).
22. Vollebergh, M.A. et al. An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Ann. Oncol. 22, 1561-1570 (2011).
23. Watkins, J.A., Irshad, S., Grigoriadis, A. & Tutt, A.N. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers. Breast Cancer Res. 16, 211 (2014).
24. Graeser, M. et al. A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin. Cancer Res. 16, 6159-6168 (2010).
25. Lord, C.J. & Ashworth, A. BRCAness revisited. Nat. Rev. Cancer 16, 110-120 (2016).
26. Bentley, D.R. et al. Accurate whole human genome sequencing using reversible terminator chemistry. Nature 456, 53-59 (2008).
27. Nik-Zainal, S. et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 534, 47-54 (2016).
28. Morganella, S. et al. The topography of mutational processes in breast cancer genomes. Nat. Commun. 7, 11383 (2016).
29. Nik-Zainal, S. et al. Mutational processes molding the genomes of 21 breast cancers. Cell 149, 979-993 (2012).
30. Nik-Zainal, S. et al. The life history of 21 breast cancers. Cell 149, 994-1007 (2012).
31. Alexandrov, L.B. et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013).
32. Waddell, N. et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518, 495-501 (2015).
33. Bailey, P. et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531, 47-52 (2016).
34. Patch, A.M. et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature 521, 489-494 (2015).
35. Alexandrov, L.B., Nik-Zainal, S., Siu, H.C., Leung, S.Y. & Stratton, M.R. A mutational signature in gastric cancer suggests therapeutic strategies. Nat. Commun. 6, 8683 (2015).
36. Stefansson, O.A. et al. Genomic and phenotypic analysis of BRCA2 mutated breast cancers reveals co-occurring changes linked to progression. Breast Cancer Res. 13, R95 (2011).
37. Yates, L.R. et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat. Med. 21, 751-759 (2015).
38. Rodriguez, A.A. et al. DNA repair signature is associated with anthracycline response in triple negative breast cancer patients. Breast Cancer Res. Treat. 123, 189-196 (2010).
39. Chappuis, P.O. et al. A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer. J. Med. Genet. 39, 608-610 (2002).
40. Lee, M.S. et al. Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays. Cancer Res. 70, 4880-4890 (2010).
41. Edwards, S.L. et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451, 1111-1115 (2008).
42. Sakai, W. et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451, 1116-1120 (2008).
43. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-1760 (2009).
44. Ye, K., Schulz, M.H., Long, Q., Apweiler, R. & Ning, Z. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinformatics 25, 2865-2871 (2009).
45. Zerbino, D.R. & Birney, E. Velvet: algorithms for de novo short read assembly using de Bruijn graphs. Genome Res. 18, 821-829 (2008).
46. Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C., Campbell, P.J. & Stratton, M.R. Deciphering signatures of mutational processes operative in human cancer. Cell Reports 3, 246-259 (2013).
47. Alexandrov, L.B. et al. Clock-like mutational processes in human somatic cells. Nat. Genet. 47, 1402-1407 (2015).
48. Van Loo, P. et al. Allele-specific copy number analysis of tumors. Proc. Natl. Acad. Sci. USA 107, 16910-16915 (2010).
49. Abkevich, V. et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br. J. Cancer 107, 1776-1782 (2012).
50. Natrajan, R. et al. Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast. J. Pathol. 232, 553-565 (2014).
51. Tibshirani, R. Regression shrinkage and selection via the lasso. J. R. Stat. Soc. Series B Stat. Methodol. 58, 267-288 (1996).